First among equals: The cancer cell hierarchy

References

• Hope K J, Jin L, Dick J E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738–743
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha M S, Benito-Hernandez A, Morrison S J, Clarke M F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci (USA) 2003; 100: 3983–3988
   PubMed Web of Science ®Google Scholar
• Singh S K, Clarke I D, Terasaki M, Bonn V E, Hawkins C, Squire J, Dirks P B. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821–5828
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick J E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–737
   PubMed Web of Science ®Google Scholar
• Collins A T, Berry P A, Hyde C, Stower M J, Maitland N J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946–10951
   PubMed Web of Science ®Google Scholar
• Mendelsohn M L. The growth fraction: a new concept applied to tumors. Science 1960; 132: 1496
   Web of Science ®Google Scholar
• Mendelsohn M L. Chronic infusion of iritiated ihymidine into mice with tumors. Science 1962; 135: 213
   PubMed Web of Science ®Google Scholar
• Mendelsohn M L. Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. III. The growth fraction. J Natl Cancer Inst 1962; 28: 1015
   PubMed Web of Science ®Google Scholar
• Wylie C V, Nakane P K, Pierce G B. Degree of differentiation in nonproliferating cells of mammary carcinoma. Differentiation 1973; 1: 11–20
   Google Scholar
• Steel G G, Lamerton L F. The growth rate of human tumors. Br J Cancer 1966; 20: 74–86
   PubMed Web of Science ®Google Scholar
• Steel G G. Cell loss as a factor in the growth rate of human tumors. Eur J Cancer 1967; 3: 381–387
   PubMedGoogle Scholar
• Clarkson B. Consideration of the cell cycle in chemotherapy of acute leukemia. Current concepts in the management of lymphoma and leukemia, J E Ultmann, M L Griem, W H Kirsten, R W Wissler. Springer-Verlag, Berlin 1970; 88–118
   Google Scholar
• Clarkson B D. Review of recent studies of cellular proliferation in acute leukemia. Natl Cancer Inst Monogr 1969; 30: 81–120
   PubMedGoogle Scholar
• Frei E, Freireich E J. Progress and perspectives in the chemotherapy of acute leukemia. Advances in chemotherapy, F H Goldlin, R J Schnitzer. Academic Press, New York 1965; 269
   Google Scholar
• Clarkson B, Fried J, Strife A, Sakai Y, Ota K, Okita T. Studies of cellular proliferation in human leukemia. 3. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days. Cancer 1970; 25: 1237–1260
   PubMed Web of Science ®Google Scholar
• Burchenal J H. Long-term survivors in acute leukemia and Burkitt's tumor. Cancer 1968; 21: 595–599
   PubMed Web of Science ®Google Scholar
• Bush R S, Hill R P. Biologic discussions augmenting radiation effects and model systems. Laryngoscope 1975; 85: 1119–1133
   PubMed Web of Science ®Google Scholar
• Moore J V, Hendry J H, Hunter R D. Dose-incidence curves for tumour control and normal tissue injury, in relation to the response of clonogenic cells. Radiother Oncol 1983; 1: 143–157
   PubMedGoogle Scholar
• Salmon S E, Hamburger A W, Soehnlen B, Durie B G, Alberts D S, Moon T E. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978; 298: 1321–1327
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645–648
   PubMed Web of Science ®Google Scholar
• Singh S K, Hawkins C, Clarke I D, Squire J A, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396–401
   PubMed Web of Science ®Google Scholar
• Southam C M, Brunschwig A, Dizon Q. Autologous and homologous transplantation of human cancer. Biological interactions in normal and neoplastic growth, M J Brennan, W L Simpson. Little, Brown and Company, Boston, MA 1962; 723–738
   Google Scholar
• Southam C M, Brunschwig A. Quantitative studies of autotransplantation of human cancer—preliminary report. Cancer 1961; 14: 971
   Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Freeman J A. The ultrastructure and genesis of Auer bodies. Blood 1960; 15: 449–465
   PubMed Web of Science ®Google Scholar
• Stass S A, Lanham G R, Butler D, Williams D L, Peiper S C, Kalwinsky D K, Dahl G V. Auer rods in mature granulocytes: a unique morphologic feature of acute myelogenous leukemia with maturation. Am J Clin Pathol 1984; 81: 662–665
   PubMed Web of Science ®Google Scholar
• Davies A R. Auer bodies in mature neutrophils. Jama 1968; 203: 895
   PubMed Web of Science ®Google Scholar
• Bainton D F, Friedlander L M, Shohet S B. Abnormalities in granule formation in acute myelogenous leukemia. Blood 1977; 49: 693–704
   PubMed Web of Science ®Google Scholar
• Fialkow P J, Singer J W, Adamson J W, Vaidya K, Dow L W, Ochs J, Moohr J W. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood 1981; 57: 1068–1073
   PubMed Web of Science ®Google Scholar
• Fearon E R, Burke P J, Schiffer C A, Zehnbauer B A, Vogelstein B. Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med 1986; 315: 15–24
   PubMed Web of Science ®Google Scholar
• Jacobson R J, Temple M J, Singer J W, Raskind W, Powell J, Fialkow P J. A clonal complete remission in a patient with acute nonlymphocytic leukemia originating in a multipotent stem cell. N Engl J Med 1984; 310: 1513–1517
   PubMed Web of Science ®Google Scholar
• Fialkow P J, Singer J W, Raskind W H, Adamson J W, Jacobson R J, Bernstein I D, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 1987; 317: 468–473
   PubMed Web of Science ®Google Scholar
• Lajtha L G. Which are the leukaemic cells. Blood Cells 1981; 7: 45–62
   PubMedGoogle Scholar
• Foulds L. The experimental study of tumor progression: a review. Cancer Res 1954; 14: 327–339
   PubMed Web of Science ®Google Scholar
• van Duuren B L, Sivak A, Katz C, Seidman I, Melchionne S. The effect of aging and interval between primary and secondary treatment in two-stage carcinogenesis on mouse skin. Cancer Res 1975; 35: 502–505
   PubMed Web of Science ®Google Scholar
• Horton S J, Grier D G, McGonigle G J, Thompson A, Morrow M, de Silva I, et al. Continuous MLL-ENL expression is necessary to establish a ‘Hox Code’ and maintain immortalization of hematopoietic progenitor cells. Cancer Res 2005; 65: 9245–9252
   PubMed Web of Science ®Google Scholar
• Cozzio A, Passegue E, Ayton P M, Karsunky H, Cleary M L, Weissman I L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029–3035
   PubMed Web of Science ®Google Scholar
• Huntly B J, Shigematsu H, Deguchi K, Lee B H, Mizuno S, Duclos N, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6: 587–596
   PubMed Web of Science ®Google Scholar
• Jamieson C H, Ailles L E, Dylla S J, Muijtjens M, Jones C, Zehnder J L, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657–667
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87: 4789–4796
   PubMed Web of Science ®Google Scholar
• Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118–3122
   PubMed Web of Science ®Google Scholar
• Bose S, Deininger M, Gora-Tybor J, Goldman J M, Melo J V. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367
   PubMed Web of Science ®Google Scholar
• Limpens J, de Jong D, van Krieken J H, Price C G, Young B D, van Ommen G J, Kluin P M. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991; 6: 2271–2276
   PubMed Web of Science ®Google Scholar
• Trumper L, Pfreundschuh M, Bonin F V, Daus H. Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals. Br J Haematol 1998; 103: 1138–1144
   PubMed Web of Science ®Google Scholar
• Maes B, Vanhentenrijk V, Wlodarska I, Cools J, Peeters B, Marynen P, de Wolf-Peeters C. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells. Am J Pathol 2001; 158: 2185–2193
   PubMed Web of Science ®Google Scholar
• Marcucci G, Strout M P, Bloomfield C D, Caligiuri M A. Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. Cancer Res 1998; 58: 790–793
   PubMed Web of Science ®Google Scholar
• Disperati P, Ichim C V, Tkachuk D, Chun K, Schuh A C, Wells R A. Progression of myelodysplasia to acute lymphoblastic leukaemia: Implications for disease biology. Leuk Res 2006; 30: 233–239
   PubMed Web of Science ®Google Scholar
• Blackstock A M, Garson O M. Direct evidence for involvement of erythroid cells in acute myeloblastic leukaemia. Lancet 1974; 2: 1178–1179
   PubMed Web of Science ®Google Scholar
• Ferraris A M, Raskind W H, Bjornson B H, Jacobson R J, Singer J W, Fialkow P J. Heterogeneity of B cell involvement in acute nonlymphocytic leukemia. Blood 1985; 66: 342–344
   PubMed Web of Science ®Google Scholar
• Jensen M K, Killmann S A. Additional evidence for chromosome abnormalities in the erythroid precursors in acute leukaemia. Acta Med Scand 1971; 189: 97–100
   PubMed Web of Science ®Google Scholar
• Keinanen M, Griffin J D, Bloomfield C D, Machnicki J, de la Chapelle A. Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. N Engl J Med 1988; 318: 1153–1158
   PubMed Web of Science ®Google Scholar
• Suciu S, Zeller W, Weh H J, Hossfeld D K. Immunophenotype of mitotic cells with clonal chromosome abnormalities demonstrating multilineage involvement in acute myeloid leukemia. Cancer Genet Cytogenet 1993; 70: 1–5
   PubMed Web of Science ®Google Scholar
• Blair A, Hogge D E, Sutherland H J. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(−)/HLA-DR. Blood 1998; 92: 4325–4335
   PubMed Web of Science ®Google Scholar
• Curtis J E, Messner H A, Hasselback R, Elhakim T M, McCulloch E A. Contributions of host- and disease-related attributes to the outcome of patients with acute myelogenous leukemia. J Clin Oncol 1984; 2: 253–259
   PubMed Web of Science ®Google Scholar
• Sutherland H, Blair A, Vercauteren S, Zapf R. Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long-term proliferation in vitro. Br J Haematol 2001; 114: 296–306
   PubMed Web of Science ®Google Scholar
• Hill R P, Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989; 16: 513–518
   PubMed Web of Science ®Google Scholar
• Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver R T, Druker B J, Goldman J M, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937
   PubMed Web of Science ®Google Scholar
• Bhatia R, Holtz M, Niu N, Gray R, Snyder D S, Sawyers C L, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–4707
   PubMed Web of Science ®Google Scholar
• Chu S, Xu H, Shah N P, Snyder D S, Forman S J, Sawyers C L, Bhatia R. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093–2098
   PubMed Web of Science ®Google Scholar
• Michor F, Hughes T P, Iwasa Y, Branford S, Shah N P, Sawyers C L, Nowak M A. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267–1270
   PubMed Web of Science ®Google Scholar
• Friend C, Scher W, Holland J G, Sato T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci (USA) 1971; 68: 378–382
   PubMed Web of Science ®Google Scholar
• Andreeff M, Stone R, Michaeli J, Young C W, Tong W P, Sogoloff H, et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80: 2604–2609
   PubMed Web of Science ®Google Scholar
• Lichtman M A. Differentiation versus maturation of neoplastic hematopoietic cells: an important distinction. Blood Cells Mol Dis 2001; 27: 649–652
   PubMed Web of Science ®Google Scholar
• Siminovitch L, McCulloch E A, Till J E. The distribution of colony-forming cells among spleen colonies. J Cell Comp Physiol 1963; 62: 327–336
   PubMedGoogle Scholar
• Till J E, McCulloch E A, Siminovitch L. A stochastic model of stem cell proliferation based on the growth of spleen colony-forming cells. Proc Natl Acad Sci (USA) 1964; 51: 29–36
   PubMed Web of Science ®Google Scholar
• Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978; 4: 7–25
   PubMedGoogle Scholar
• Lord B I. The architecture of bone marrow cell populations. Int J Cell Cloning 1990; 8: 317–331
   PubMedGoogle Scholar
• Calvi L M, Adams G B, Weibrecht K W, Weber J M, Olson D P, Knight M C, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841–846
   PubMed Web of Science ®Google Scholar
• Lord B I, Hendry J H. The distribution of haemopoietic colony-forming units in the mouse femur, and its modification by x rays. Br J Radiol 1972; 45: 110–115
   PubMed Web of Science ®Google Scholar
• Lord B I, Testa N G, Hendry J H. The relative spatial distributions of CFUs and CFUc in the normal mouse femur. Blood 1975; 46: 65–72
   PubMed Web of Science ®Google Scholar
• Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149–161
   PubMed Web of Science ®Google Scholar
• Zhang J, Niu C, Ye L, Huang H, He X, Tong W G, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836–841
   PubMed Web of Science ®Google Scholar
• Reya T, Duncan A W, Ailles L, Domen J, Scherer D C, Willert K, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409–414
   PubMed Web of Science ®Google Scholar
• Jian H, Shen X, Liu I, Semenov M, He X, Wang X F. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev 2006; 20: 666–674
   PubMed Web of Science ®Google Scholar
• Alexson T O, Hitoshi S, Coles B L, Bernstein A, van der Kooy D. Notch signaling is required to maintain all neural stem cell populations – irrespective of spatial or temporal niche. Dev Neurosci 2006; 28: 34–48
   PubMed Web of Science ®Google Scholar
• Duncan A W, Rattis F M, DiMascio L N, Congdon K L, Pazianos G, Zhao C, et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 2005; 6: 314–322
   PubMed Web of Science ®Google Scholar
• Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423: 255–260
   PubMed Web of Science ®Google Scholar
• Nakauchi H, Oguro H, Negishi M, Iwama A. Polycomb gene product Bmi-1 regulates stem cell self-renewal. Ernst Schering Res Found Workshop 2005; 85–100
   PubMedGoogle Scholar
• Iwama A, Oguro H, Negishi M, Kato Y, Morita Y, Tsukui H, et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 2004; 21: 843–851
   PubMed Web of Science ®Google Scholar
• Beslu N, Krosl J, Laurin M, Mayotte N, Humphries K R, Sauvageau G. Molecular interactions involved in HOXB4-induced activation of HSC self-renewal. Blood 2004; 104: 2307–2314
   PubMed Web of Science ®Google Scholar
• Ema H, Sudo K, Seita J, Matsubara A, Morita Y, Osawa M, et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev Cell 2005; 8: 907–914
   PubMed Web of Science ®Google Scholar
• Zeng H, Yucel R, Kosan C, Klein-Hitpass L, Moroy T. Transcription factor Gfi1 regulates self-renewal and engraftment of hematopoietic stem cells. Embo J 2004; 3: 4116–4125
   Web of Science ®Google Scholar
• Hock H, Hamblen M J, Rooke H M, Schindler J W, Saleque S, Fujiwara Y, Orkin S H. Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature 2004; 431: 1002–1007
   PubMed Web of Science ®Google Scholar
• Kato Y, Iwama A, Tadokoro Y, Shimoda K, Minoguchi M, Akira S, et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med 2005; 202: 169–179
   PubMedGoogle Scholar
• Burns C E, Traver D, Mayhall E, Shepard J L, Zon L I. Hematopoietic stem cell fate is established by the Notch-Runx pathway. Genes Dev 2005; 19: 2331–2342
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhang Y, Joe G J, Pompetti R, Emerson S G. NF-Ya activates multiple hematopoietic stem cell (HSC) regulatory genes and promotes HSC self-renewal. Proc Natl Acad Sci (USA) 2005; 102: 11728–11733
   PubMed Web of Science ®Google Scholar
• Iwasaki H, Somoza C, Shigematsu H, Duprez E A, Iwasaki-Arai J, Mizuno S, et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 2005; 106: 1590–1600
   PubMed Web of Science ®Google Scholar
• Blair A, Sutherland H J. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000; 28: 660–671
   PubMed Web of Science ®Google Scholar
• Blair A, Hogge D E, Ailles L E, Lansdorp P M, Sutherland H J. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997; 89: 3104–3112
   PubMed Web of Science ®Google Scholar
• Jordan C T, Upchurch D, Szilvassy S J, Guzman M L, Howard D S, Pettigrew A L, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777–1784
   PubMed Web of Science ®Google Scholar